pharm - immunomodulators Flashcards
cyclosporine MOA
binds to cycophilins
blocks differentiation and activation of T cells by binding to calcineurin
cyclosporin use
post transplantation anti rejection, some autoimmune dxs
cyclosporin tox
nephrotox, hypertension, hyperglycemia, tremor, gingival hyperplasia, tremor, hirsutism
tacrolimus tox
nephrotox, hypertension, hyperglycemia, tremor, tremor,
tacrolimus MOA
bids to FK-binding protiein, blocks differentiation and activation of T cells
tacrolimus use
potent antirejection
sirolimus/rapamycin MOA
inhibits mTOR, inhibits T cell proliferation in reponse to IL-2
sirolimus/rapamycin use
post transplant in kidney graft. Also in drug eluding stents
sirolimus/rapamycin tox
hyperlipidemia, thrombocytopenia, leukopenia
azathrioprine MOA
precursor to 6-mercaptopurine that interferes with metabolism and synthesis of nucleic acids
azathrioprine use
kidney transplant, autoimmune disorders
azathrioprine tox
bone marrow supression (increased by allopurinol)
muromonab-CD3 (OKT3) MOA
monoclonal antibidy that binds to and blocks CD3 on T cell
muromonab-CD3 (OKT3) use
immunosupression after kidney graft
muromonab-CD3 (OKT3) tox
cytokine release storm, hypersensitivity
use of aldesleukin (IL-2)
renal cell carcinoma, metastatic melanoma
use of erythopestin
anemias (esp in renal failure)
use of filgrastim
recovery of bone marrow
use of sardramostim (Granulocyte-macrophage colony stimulating factor)
recovery of bone marrow
use of a-interferon
hep B/C, KS, leukemia, melanoma
use of B interferon
MS
use of G-interferon
chronic granulomatous disease
Oprelvekin (IL-11) use
thrombocytopenia
use of thrombopeoiten
thrombocytopenia
digoxin immune Fab use
digoxin OD
infliximab use
(target’s TNF-a) crohn’s, RA, psoratic arthritis, ankylosing spondy
adalimumab use
(target’s TNF-a) crohn’s, RA, psoratic arthritis, ankylosing spondy
abiciximab use
targets gycoprotein IIb/IIIa - preents cardiac ischemia in unstable angina and in pts treated with PCI
trastuzumab (herceptin) use
HER2 overexpressing breast cancer
rituximab use
targets CD20 - B cell non-hodgkin’s lymphoma
omalizumab use
targets IgE - severe asthma